Cargando…
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
OBJECTIVE: This study aimed to evaluate the safety, efficacy, and feasibility of the rituximab, fotemustine, pemetrexed, and dexamethasone (R-FPD) regimen followed by whole-brain radiotherapy (WBRT) for patients with primary central nervous system lymphoma (PCNSL). METHODS: A prospective, single-cen...
Autores principales: | Wu, Jingjing, Gao, Fenghua, Wang, Wenhua, Zhang, Xudong, Dong, Meng, Zhang, Lei, Li, Xin, Li, Ling, Sun, Zhenchang, Wang, Xinhua, Fu, Xiaorui, Zhu, Linan, Ding, Mengjie, Niu, Songtao, Li, Zhaoming, Chang, Yu, Nan, Feifei, Yan, Jiaqian, Yu, Hui, Wu, Xiaolong, Zhou, Zhiyuan, Zhang, Jieming, Zhang, Mingzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334761/ https://www.ncbi.nlm.nih.gov/pubmed/34633776 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0026 |
Ejemplares similares
-
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018) -
Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020) -
TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
por: Zhu, Linan, et al.
Publicado: (2018) -
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019) -
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)